AstraZeneca now says its vaccine is 76% effective in battling COVID-19 -- but that comes amid speculation about the shot and whether it will be approved in the U.S. at all.

As vaccine access expands and demand overall for the shot is high, some are still reluctant to roll up their sleeves.

In fact, a News 12 poll earlier this week found that nearly 25% of the more than 800 people who responded will not get the vaccine.

The latest vaccine information could be causing some more hesitancy. AstraZeneca was criticized for using outdated information when it said its vaccine was 79% effective at preventing symptomatic COVID-19. The company just updated that figure to 76% -- though it maintains its shot is 100% effective at stopping severe illness and death.

VACCINE INFORMATION: Check to see if you are eligible

VACCINE TRACKER: Check the latest vaccine statistics from New York

Also on Thursday, Denmark prolonged its suspension of the AstraZeneca vaccine over concerns about blood clotting. But many of the European countries that had previously stopped administering it have now resumed its use after conducting their own safety reviews.

There are also questions about whether or not Johnson & Johnson will meet its goal of delivering 20 million doses to the United States by the end of the month.

Experts say this set of mistakes could add to vaccine hesitancy.

"There remain many people that are concerned whether there's appropriate safety and several other reasons why they've chosen not to get the vaccine," says Dr. David Hirschwerk, with Northwell Health. "And when there is a misstep with communications and how data is presented, it does not help the situation."

The AstraZeneca vaccine does not have emergency-use authorization in the United States right now.